A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer

A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer

Hai-ying Wang, Jun-feng Chu, Yan Zhao, Hong Tang, Li-li Wang, Meng-qiang Zhou, Zheng Yan, Yan-yan Liu, Zhi-hua Yao Department of Internal Medicine, Henan Cancer Hospital or Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, People’s Republic of ChinaCorrespondence: Zhi-h...

Full description

Bibliographic Details
Main Authors: Wang H, Chu J, Zhao Y, Tang H, Wang L, Zhou M, Yan Z, Liu Y, Yao Z
Format: Article
Language:English
Published: Dove Medical Press 2020-05-01
Series:Cancer Management and Research
Subjects:
anlotinib
chemotherapy
toxicity
efficacy
advanced non-small cell lung cancer
Online Access:https://www.dovepress.com/a-trial-of-the-safety-and-efficacy-of-chemotherapy-plus-anlotinib-vs-c-peer-reviewed-article-CMAR

Internet

https://www.dovepress.com/a-trial-of-the-safety-and-efficacy-of-chemotherapy-plus-anlotinib-vs-c-peer-reviewed-article-CMAR

Similar Items